New HIV Prevention Medicine Lenacapavir Arrives In South Africa

South Africa has taken a significant step in its fight against HIV with the arrival of its first batch of Lenacapavir. The Department of Health confirmed that nearly 38,000 doses of the long-acting injectable have now reached the country.

The introduction of the medication is expected to strengthen national prevention strategies by providing an alternative for individuals who face challenges with current HIV prevention methods.

Twice-Yearly Injection Offers Hope to High-Risk Groups

Lenacapavir, administered just twice a year, is designed to improve adherence and expand access to HIV prevention—particularly among vulnerable populations. These include young women, sex workers, and men who have sex with men, who often face barriers to consistent prevention care.

YOU MAY ALSO LIKE: Fannie Nkosi To Spend Another Weekend Behind Bars As Bail Bid Stalled Over Firearms, Cash And Secret Dossiers

Health officials believe the rollout could play a key role in reducing new HIV infections and advancing the country’s ambition to eliminate AIDS as a public health threat by 2030.

Government Prepares Phased Rollout of ‘Game-Changing’ HIV Tool

The Department of Health is expected to unveil a phased implementation plan in the coming weeks as preparations continue for the official launch.

YOU MAY ALSO LIKE: Pensioner And Teen Arrested For Illegal Firearms In Cape Flats Crackdown

Department spokesperson Foster Mohale said:m “The department will, in the next few weeks, announce the official launch of this game changer where the phased implementation plan will be outlined.

“Lenacapavir is preventive medicine, not a vaccine, considered one of the most exciting HIV prevention advances in years,”